Key Drivers
- High gross margins
- Large operating burn
- Negative equity
AIAI Summary
BridgeBio has shifted from a binary R&D bet to a commercial-stage operator—Attruby's ~95% gross margins mean a successful scale to management's ~30% volume target could rapidly convert to positive FCF, but the company's negative equity and concentrated long-term debt make it highly vulnerable to any launch, payer, or IP setback. Investors should model scenarios stressing Attruby adoption ±30–50%, require visible SG&A moderation post-readouts, and prioritize solvency metrics (debt covenants, convertible overhang) as near-term gating factors for valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Large operating burn
- •Negative equity
BBIO pairs very high product margins and a healthy cash buffer (current ratio 2.77) with outsized operating losses, negative equity and large noncurrent debt, creating short-term liquidity but acute solvency and valuation risks.
Price Behavior
Key Price Behavior Insights:
- •Sideways trend
- •Elevated volatility
- •Mid-$65 bounce
Over the last month BBIO traded flat (68.14→68.54) with elevated short-term volatility—~10% swings—bouncing off mid-$65 support but repeatedly failing to hold into the low-$70s/74.32 resistance.
~10% intraperiod swings and choppy highs/lows despite flat net change over the last month
Sentiment & News
Key News Insights:
- •Attruby commercial traction
- •Positive FORTIFY data
- •Ongoing IP risk
BridgeBio beat revenue estimates despite a $1.00/share loss, highlighted commercial momentum for Attruby and encouraging Phase 3 FORTIFY/BBP-418 data while navigating tafamidis patent scrutiny and mixed insider/institutional flows.
The combination of commercial progress and encouraging clinical readouts should bolster medium-term value, but patent uncertainty and insider selling could keep near-term volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings